Biopharma Company Delists from OTCQB, Remains on AIM Market
Biopharma company delists from OTCQB, continues trading on AIM Market of London Stock Exchange.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Due to low trading volume and the ensuing administrative
requirements, a biopharmaceutical company that focusses on the development and
commercialisation of novel medications targeting diseases with a high unmet
medical need, voluntarily delists its ordinary shares ("Ordinary
Shares") from trading on the OTCQB Market. Monday, July 29, 2024 will be
the Company's final day of trading on the OTCQB Market.
"POLB" will continue to be Poolbeg's ticker on the
AIM Market of the London Stock Exchange. Poolbeg's Ordinary Shares will
continue to trade on the AIM Market following its delisting from the OTCQB
market.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Ab Science überarbeitet Studienzeitpläne nach drei GCP-Inspektionen
Novo Nordisk unterzeichnet einen $2,6B-Deal mit Hengrui für orales GLP-1
Discussion